drugset / Trial / NCT07517653
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma
Timeline
- Start
- 2026-04-01
- Primary completion
- 2028-11-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | — | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | — |